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Background: The relatively low budget impact of orphan drugs is often used as an argument in reimbursement
decisions. However, overall, the budget impact of orphan drugs can still be substantial. In this study, we assess the
uptake and budget impact of orphan drugs in the Netherlands.
Methods: We examined the number of orphan drugs, the number of patients and budget impact of orphan drugs
in the Netherlands in the period 2006 to 2012, both for inpatient and outpatient orphan drugs. Budget impact was
provided in absolute numbers and relative to total pharmaceutical spending.
Results: The number of orphan drugs and patients treated increased substantially over the period studied. Overall,
budget impact increased substantially over a period of six years, both in absolute terms (326% increase) as well as
relative to total pharmaceutical spending (278% increase). Growth rates decreased over time. In 2012, 17% of
available drugs had an individual budget impact of more than €10 million per year.
Conclusions: Individual budget impact of orphan drugs is often limited, although exceptions exist. However, in
total, the budget impact of orphan drugs is considerable and has grown substantially over the years. This could
potentially influence reimbursement decisions for orphan drugs in the future.
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The introduction of orphan drug legislation in various
jurisdictions has played an important role for the devel-
opment of orphan drugs; since European legislation was
passed in 2000, 73 drugs for orphan indications were
licensed [1]. However, on a national level this also poses
policy makers for difficult decisions concerning reim-
bursement, as illustrated by examples from the United
Kingdom and the Netherlands [2,3]. On the one hand,
therapies are developed for diseases that, next to being
rare, are life-threatening and chronically debilitating by
definition [4]. On the other hand, orphan drug prices can
be enormous, as pharmaceutical companies recoup their
investments in research and development on the small pa-
tient population. The high prices of orphan drugs place
decision makers for a difficult task; cost-effectiveness ra-
tios for these drugs are often very high, implying that the
money spent on orphan drugs might be spend more* Correspondence: kanters@bmg.eur.nl
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unless otherwise stated.efficiently in other disease areas. However, there are also
arguments in favor of granting reimbursement to orphan
drugs. Ethical considerations, the lack of alternative treat-
ments and severity of the disease all apply to the case of
orphan drugs [5].
Budget impact is yet another criterion used in reim-
bursement decisions [6,7]. For orphan drugs, the impact
on the pharmaceutical budget is limited due to the small
number of patients, let alone the impact on the entire
healthcare budget. Although this proposition holds for
individual orphan drugs, the combined budget impact of
all available orphan drugs might be considerable, espe-
cially as the number of orphan drugs on the market is still
increasing. Various studies in several European countries
have shown the increasing share of pharmaceutical spend-
ing that is spent on orphan drugs [8-11]. Moreover, these
studies have shown that differences between countries
exist. In this study we assess the uptake and overall budget
impact of orphan drugs in the Netherlands. As such, the
results of this study can be useful for Dutch policymakers,
as well as for validating results from earlier studies inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Uptake and budget impact of orphan drugs in
the Netherlands
2006 2007 2008 2009 2010 2011 2012
Number of orphan drugs
Outpatient 9 15 18 22 25 30 32
Inpatient 2 7 8 9 11 11 11*
Total 11 22 26 31 36 41 43
Number of patients treated with orphan drugs
Outpatient 2,149 3,457 4,410 6,024 7,621 8,250 9,226
Inpatient 40 146 215 469 531 536 536*
Total 2,189 3,603 4,625 6,493 8,152 8,786 9,762
Budget impact of orphan drugs (millions)
Outpatient €52.7 €68.7 €97.8 €118.1 €141.6 €156.2 €175.2
Inpatient €8.5 €29.2 €60.7 €74.6 €84.3 €85.1 €85.1*
Total €61.2 €97.9 €158.6 €192.7 €225.9 €241.4 €260.4
*For inpatient drugs, figures for 2012 were assumed equal to 2011.
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Methods
In the Netherlands, outpatient and inpatients orphan
drugs are financed differently. Firstly, outpatient drugs
are financed through the common Drug Reimbursement
System (GVS). Outpatient cancer orphan drugs were
transferred to the specialist drugs list in 2013. Secondly,
inpatient drugs were financed through a specific policy
rule on orphan drugs (until 2012) and since 2012 through
an “add-on” diagnosis treatment combination (DBC). We
examined the number of orphan drugs in the Netherlands,
the number of patients using them and the orphan drugs’
budget impact.
Outpatient drugs
For outpatient drugs we examined the Drug Information
Project (GIP) database hosted by the Health Care Insur-
ance Board (CVZ) [12]. The GIP database is publicly ac-
cessible and contains information on the use and costs of
medicines and medical devices. With respect to medicines,
the database contains detailed information on number of
patients, usage and expenditures. Some orphan drugs were
also prescribed for non-orphan indications. For these
drugs, only data related to orphan indications was taken
into account. Prices were calculated by dividing drug’s
budget impact by the number of defined daily doses multi-
plied by 365.25 to get price of treatment per year.
Inpatient drugs
From 2006 to 2012, inpatient drugs were financed through
a specific policy rule on orphan drugs. When applying for
inclusion on the policy rule, pharmaceutical companies
had to make predictions on the number of users, prices
and budget impact of the drug. Furthermore, after a reim-
bursement period of four years, pharmaceutical compan-
ies had to submit an outcomes research report with,
among other aspects, clinical outcomes, observed number
of users and budget impact. The primary sources of infor-
mation for the current study were the outcomes research
reports and the policy rule applications. When outcomes
research reports and policy rule applications were not
available, data on an aggregated level from the Monitor
Expensive Drugs were used [13].
Analyses
Budget impact was expressed in euros and as a percentage
of total pharmaceutical spending. Total pharmaceutical
spending in the Netherlands (orphan drugs and non-
orphan drugs) was derived from the GIP database for
outpatient drugs. Total pharmaceutical spending on in-
patient drugs were derived from FarmInform [14]. Totalpharmaceutical spending resulted from the summation of
inpatient and outpatient drugs spending.
In addition to the analyses with regard to all orphan
drugs combined, characteristics are provided for the five
orphan drugs ranked highest with regard to the number
of patients treated, the price of the orphan drug and the
individual drug’s budget impact.
For some inpatient drugs, data was not available for all
years. In these cases, the last observation was used for
later years, implying a conservative scenario. As a sensi-
tivity analysis, the individual drugs’ growth rate for the
last known year was used for extrapolation instead.Results
Table 1 shows the uptake of orphan drugs and evolution
of orphan drug spending over time in the Netherlands.
Considering uptake of orphan drugs, both the number
of drugs and the number of patients almost quadrupled
over the studied period. Both factors contributed to the
increase in budget impact of orphan drugs over time, both
for inpatient and outpatient drugs. For inpatient drugs,
the number of patients was relatively stable for each drug.
For outpatient drugs, the number of users increased sub-
stantially; with an average growth of 168 patients over the
study period.
For inpatient drugs, prices were constant over the time
period studied. The average annual treatment costs for
inpatient drugs was €255,615 (SD = 223,306). The average
annual treatment costs for outpatient drugs was €40,679
in 2012 (SD = 45,283). For outpatient drugs, some vari-
ation was observed over the study period, but for most
drugs price changes were modest. For 39.3% of the in-
patient drugs, prices decreased with more than 2%. In
contrast, prices increased with more than 2% for 17.9% of
Kanters et al. Orphanet Journal of Rare Diseases 2014, 9:154 Page 3 of 5
http://www.ojrd.com/content/9/1/154drugs. On average, drug prices slightly decreased over
time (−1.2%).
Table 1 further shows that over a period of seven
years, the total expenditure on orphan drugs quadrupled.
The growth rate was decreasing over time; from 60.1%
in the period 2006 to 2007 to 7.9% in 2011–2012. The
absolute growth in budget impact was largest for out-
patient drugs. The relative growth in budget impact over
seven years was largest for inpatient drugs.
Figure 1 provides the development of budget impact of
orphan drugs over time as a percentage of total pharma-
ceutical spending. The proportion of total pharmaceutical
spending spent on orphan drugs almost quadrupled from
1.1% in 2006 to 4.2% 2012. The relative growth rate
decreased over time. Total pharmaceutical spending in-
creased with 12.6% in the period 2006–2012.
Table 2 shows the orphan drugs that were most often
used in 2012. In 2012, a total of 1,485 patients received
imatinib. The most-often used inpatient drug was tra-
bectedin (Yondelis®, 240 patients). More than 60% of all
orphan drug receiving patients in the Netherlands re-
ceived one of the five most-used drugs, which are listed
in Table 2. Lenalidomide (Revlimid®) was the drug with
the biggest increase in the number of users over time;
from 79 users in 2007 to 1,089 in 2012.
Yearly treatment costs exceeded €100,000 per patient
for seven inpatient drugs (63.6%) and for two outpatient
drugs (6.3%). The orphan drugs with the highest per
patient prices are provided in Table 2. Velaglucerase alfa
(VPRIV®) was the highest priced inpatient drug, with
annual per patient costs of approximately €200,000 in
2012. Tafamidis (Vyndaqel®) was the only other inpatient
drug with annual costs over €100,000. Yearly costs for
three (five) drugs were lower than €2,000 (€3,000).
Table 2 also shows the orphan drugs with the highest
budget impact in 2012. Seven out of 41 orphan drugs
(17%) had an individual budget impact exceeding €10
million; the budget impact of 18 outpatient and nine in-
patient drugs was more than €1 million in 2012. The drug0.0%
0.5%
1.0%
1.5%
2.0%
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Figure 1 Budget impact of orphan drugs as a proportion of total druwith the largest budget impact in 2012 was alglucosidase
alfa. Together, the five drugs with the largest budget im-
pact accounted for 57.7% of the total budget impact of
orphan drugs. Four drugs (one inpatient) had a cumulative
budget impact of more than €100 million over the study
period. Imanitib’s cumulative budget impact exceeded
€250 million.
Sensitivity analysis
For missing data for inpatient drugs, we used the last
observed budget impact. For drugs with a growing budget
impact over time (majority of the 11 inpatient drugs) this
might have led to an underestimation of the budget im-
pact. Extrapolation of the last observed growth rates for
individual drugs’ resulted in an additional budget impact
of €14 million in 2012. In this analysis, 4.6% of total
pharmaceutical spending would be spent on orphan drugs
in 2012. In contrast to the base case analysis, the growth
rate would be constant over time.
Discussion
In this study, we showed that the budget impact of or-
phan drugs in the Netherlands increased substantially
over time, both as a proportion of total drug spending as
well as in absolute terms. The growth in budget impact
was explained by the increasing number of orphan drugs
available and the increasing number of patients receiving
the drugs.
The proportion of total pharmaceutical spending on
orphan drugs in the Netherlands for 2007 was 1.6%;
similar to proportional spending in Spain (2.0%), Germany
(2.1%) Italy (1.5%) and France (1.7%); and higher than in
the UK (1.0%) [9]. For later years, budget impact in the
Netherlands was higher than in Belgium (1.9% in 2008,
compared to 2.6% in the Netherlands), Sweden and France
(respectively 2.5% and 3.1% in 2012, compared to 4.2% in
the Netherlands) [8,11]. It should be noted that comparing
our results to studies from other countries is difficult due
to transferability issues: inter-country differences with009 2010 2011 2012
g spending.
Table 2 Orphan drugs with highest number of users, highest prices and highest budget impact (2012)
Rank INN Trade name Setting Patients
1 Imatinib Glivec® Outpatient 1,485
2 Lenalidomide Revlimid® Outpatient 1,089
3 Sildenafil Revatio® Outpatient 1,052
4 Thalidomide Thalidomide Cellgene® Outpatient 1,030
5 Bosentan Tracleer® Outpatient 901
Rank INN Trade name Setting Cost/Patient
1 Galsulfase Naglazyme® Inpatient €600,000
1 Idursulfase Elaprase® Inpatient €600,000
3 Alglucosidase alfa Myzoyme® Inpatient €474,857*
4 Eculizumab Soliris® Inpatient €358,000
5 Aldurazyme Laronidase® Inpatient €300,000
Rank INN Trade name Setting Budget impact (millions) Cumulative budget impact
2006–2012 (millions)
1 Alglucosidase alfa Myozyme® Inpatient €40.3 €203.4
2 Imatinib Glivec® Outpatient €36.4 €251.2
3 Lenalidomide Revlimid® Outpatient €36.2 €127.4
4 Bosentan Tracleer® Outpatient €23.0 €132.4
5 Pegvisomant Somavert® Outpatient €14.3 €72.5
INN = International Nonproprietary Names; *weighted average of infantile patients (€706,666/patient) and adult patients (€422,314/patient).
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drugs and prices of orphan drugs exist [Kanters et al: Fac-
tors affecting reimbursement decisions on 11 high-
priced inpatient orphan drugs, submitted]. Furthermore,
total pharmaceutical spending differs between coun-
tries, which could also affect the proportion spent on
orphan drugs.
Two earlier studies have used a model to predict future
proportion of pharmaceutical spending spent on orphan
drugs [10,11]. Schey et al. [10] predicted the proportion of
total pharmaceutical spending spent on orphan drugs to
decrease from 2016 onwards [10]. An important element
in their model was the assumption that orphan drug
prices would decrease as a consequence of competition.
Until now, the generic orphan drugs market did not ex-
pand, and it can be questioned whether the orphan drug
market is attractive enough for generic companies to enter
the field of rare diseases. More recently, Hutchings et al.
[11] forecasted that the proportion of total drug spending
on orphan drugs in Sweden and France would increase
until 2018, after which a steady state would be reached
[11]. More research is needed to establish whether the
steady state would actually be achieved and how these fig-
ures apply to other countries.
Our results show similarities with other studies over time
increasing budget impact relative to total pharmaceutical
spending but with decreasing growth rates [10,11]. Over
time, growth rates were decreasing. This might be ex-
plained by saturation of the target population; most eligiblepatients receive the available drug. Saturation might be
especially high for these orphan drugs as alternative treat-
ments are often non-existent.
Limitations
The time period in this study was limited to a period of
seven years. Even in this relatively short time period, we
observed a substantial growth in orphan drugs spending.
A longer study period would be needed to investigate
whether the growth rates continue to decrease, and if so
whether a negative growth rate, i.e. a decreasing budget
impact, will be observed in the future. Due to a change
in financing outpatient cancer drugs since 2013, the
analyses could not be extended to 2013. Remarkably,
when a subsample of outpatient drugs that were avail-
able for 2013 (n = 26) was analyzed, a decrease (−6.0%)
of the number of patients treated was found. Despite the
decrease in the number of patients treated, an increase
in the total budget impact is observed. The growth rate
of the budget impact relative to the previous year was
modest (4.8%). Two new outpatient orphan drugs entered
the Dutch market in 2013.
To predict the future budget impact of orphan drugs in
the Netherlands, detailed information is needed on avail-
ability of individual orphan drugs in the Netherlands,
number of patients using these drugs, and prices of or-
phan drugs in the Netherlands, also in relation to generic
competition for orphan drugs. This information is yet un-
available for the Netherlands. Further research on these
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impact of orphan drugs in the Netherlands can be made.
Implications
The combined budget impact of orphan drugs is sub-
stantial and increasing. Budget impact for individual or-
phan drugs might be limited (although 17% of orphan
drugs had an individual budget impact exceeding €10
million). However, policy makers should acknowledge
the increasing budget impact of all orphan drugs. The
small budget impact might therefore not be a valid argu-
ment in discussions on reimbursement of orphan drugs,
especially as the number of orphan drugs continues to
grow and hence so will their budget impact.
Conclusions
The number of available orphan drugs and the number
of patients receiving these orphan drugs have substan-
tially increased over the last years in the Netherlands.
Accordingly, the budget impact associated with these or-
phan drugs have increased, both in absolute terms as
well as compared to the total pharmaceutical spending.
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